DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [phenyl-14C]ARV-471
Drug: [oxoisoindolin-14C]ARV-471

First Posted Date: 2023-07-05

Last Posted Date: 2023-09-13

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05930925

Locations: 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: encorafenib
Drug: ipilimumab
Drug: binimetinib
Drug: nivolumab
Drug: pembrolizumab

First Posted Date: 2023-07-03

Last Posted Date: 2025-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 150

Registration Number: NCT05926960

Locations: 🇩🇪
Universitaetsklinikum Tuebingen, Tübingen, Baden-württemberg, Germany
🇩🇪
Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
🇩🇪
Universitaetsklinikum Essen, Essen, Nordrhein-westfalen, Germany

and more 21 locations

BESPONSA Injection 1 mg Special Investigation

Completed

Conditions: Acute Lymphocytic Leukemia

First Posted Date: 2023-06-28

Last Posted Date: 2025-02-13

Lead Sponsor: Pfizer

Target Recruit Count: 421

Registration Number: NCT05923112

Locations: 🇯🇵
Pfizer, Tokyo, Japan

A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Single dose of PF-07220060 as first Tablet Formulation
Drug: Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration
Drug: Single dose of PF-07220060 as third tablet formulation
Drug: Single dose of PF-07220060 as second Tablet Formulation
Drug: Single dose of PF-07220060 as a Tablet Formulation

First Posted Date: 2023-06-28

Last Posted Date: 2024-07-26

Lead Sponsor: Pfizer

Target Recruit Count: 113

Registration Number: NCT05923411

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

Not yet recruiting

Conditions: Breast Cancer

First Posted Date: 2023-06-22

Last Posted Date: 2023-06-22

Lead Sponsor: Pfizer

Target Recruit Count: 1300

Registration Number: NCT05912933

A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07293893
Drug: Placebo

First Posted Date: 2023-06-18

Last Posted Date: 2025-04-10

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT05907395

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: ARV-471 (PF-07850327)
Drug: Letrozole
Combination Product: Palbociclib

First Posted Date: 2023-06-18

Last Posted Date: 2025-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 59

Registration Number: NCT05909397

Locations: 🇸🇰
Nemocnica na okraji mesta n o, Partizanske, Slovakia
🇺🇸
BRCR Medical Center Inc, Plantation, Florida, United States
🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States

and more 25 locations

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Phase 1

Withdrawn

Conditions: Non-small Cell Lung Cancer (NSCLC)
Solid Tumors
Breast Cancer
Ovarian Cancer
Liposarcoma
Endometrial

Interventions: Drug: PF-07224826
Combination Product: Fulvestrant

First Posted Date: 2023-06-15

Last Posted Date: 2023-11-08

Lead Sponsor: Pfizer

Registration Number: NCT05905341

A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin

Phase 1

Completed

Conditions: Pharmacokinetics
Healthy Volunteers

Interventions: Drug: Rosuvastatin
Drug: Nirmatrelvir/ritonavir

First Posted Date: 2023-06-12

Last Posted Date: 2024-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05898672

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

Phase 1

Completed

Conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)

Interventions: Biological: RSVpreF 120 µg
Biological: RSVpreF 60 µg

First Posted Date: 2023-06-12

Last Posted Date: 2025-03-06

Lead Sponsor: Pfizer

Target Recruit Count: 128

Registration Number: NCT05900154

Locations: 🇺🇸
Senders Pediatrics, South Euclid, Ohio, United States
🇺🇸
University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

and more 14 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy